Likewise, the dramatic reduction in the cost of gene sequencing, from roughly $40 million per human genome in 2003 to about $5,000 today, together with a rapid increase in computational power, is boosting the speed, accuracy, and robustness of medical diagnostic tests. That promises not only more timely and effective therapies for cancer, but also similar advances against other currently intractable diseases.